血脂作为前列腺癌发生和预后的标志?

Q Medicine

Clinical Lipidology Pub Date : 2015-04-01 DOI:10.2217/clp.14.69

R. Arthur, A. Rodríguez-Vida, G. Zadra, H. Møller, M. Hemelrijck

{"title":"血脂作为前列腺癌发生和预后的标志?","authors":"R. Arthur, A. Rodríguez-Vida, G. Zadra, H. Møller, M. Hemelrijck","doi":"10.2217/clp.14.69","DOIUrl":null,"url":null,"abstract":"Abstract With the current epidemic of lipid-related disorders and prostate cancer (PCa) in western countries, there is growing interest in the potential causal relationship between lipids and PCa. PCa is a heterogeneous disease, which undermines researchers’ ability to determine the mechanistic pathways responsible for its development and progression. Currently, detection and progression of PCa is mainly determined by prostate specific antigen, but this biomarker lacks specificity and is unable to discriminate between indolent and aggressive cancer. Nonetheless, there is evidence to suggest that lipid markers might potentially be useful in conjunction with other markers such as prostate specific antigen in improving detection and management of this disease. This review aims to highlight findings from epidemiological studies which examined the role of serum lipids in PCa occurrence and prognosis.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"98 1","pages":"145 - 165"},"PeriodicalIF":0.0000,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Serum lipids as markers of prostate cancer occurrence and prognosis?\",\"authors\":\"R. Arthur, A. Rodríguez-Vida, G. Zadra, H. Møller, M. Hemelrijck\",\"doi\":\"10.2217/clp.14.69\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract With the current epidemic of lipid-related disorders and prostate cancer (PCa) in western countries, there is growing interest in the potential causal relationship between lipids and PCa. PCa is a heterogeneous disease, which undermines researchers’ ability to determine the mechanistic pathways responsible for its development and progression. Currently, detection and progression of PCa is mainly determined by prostate specific antigen, but this biomarker lacks specificity and is unable to discriminate between indolent and aggressive cancer. Nonetheless, there is evidence to suggest that lipid markers might potentially be useful in conjunction with other markers such as prostate specific antigen in improving detection and management of this disease. This review aims to highlight findings from epidemiological studies which examined the role of serum lipids in PCa occurrence and prognosis.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"98 1\",\"pages\":\"145 - 165\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/clp.14.69\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.14.69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

摘要

随着目前脂质相关疾病和前列腺癌(PCa)在西方国家的流行，人们对脂质与前列腺癌之间潜在的因果关系越来越感兴趣。前列腺癌是一种异质性疾病，这削弱了研究人员确定其发展和进展的机制途径的能力。目前，前列腺癌的检测和进展主要由前列腺特异性抗原决定，但这种生物标志物缺乏特异性，无法区分惰性癌和侵袭性癌。尽管如此，有证据表明脂质标记物可能与其他标记物(如前列腺特异性抗原)联合使用，以改善这种疾病的检测和管理。这篇综述旨在强调流行病学研究的结果，这些研究检查了血脂在前列腺癌发生和预后中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serum lipids as markers of prostate cancer occurrence and prognosis?

Abstract With the current epidemic of lipid-related disorders and prostate cancer (PCa) in western countries, there is growing interest in the potential causal relationship between lipids and PCa. PCa is a heterogeneous disease, which undermines researchers’ ability to determine the mechanistic pathways responsible for its development and progression. Currently, detection and progression of PCa is mainly determined by prostate specific antigen, but this biomarker lacks specificity and is unable to discriminate between indolent and aggressive cancer. Nonetheless, there is evidence to suggest that lipid markers might potentially be useful in conjunction with other markers such as prostate specific antigen in improving detection and management of this disease. This review aims to highlight findings from epidemiological studies which examined the role of serum lipids in PCa occurrence and prognosis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.